DelveInsight’s "Multiple Sclerosis (MS)–Market Insights, Epidemiology, and Market Forecast–2032" report deliver an in-depth understanding of the Multiple Sclerosis (MS), historical and forecasted epidemiology as well as the market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Multiple Sclerosis (MS) market report provides current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted Multiple Sclerosis (MS) symptoms market size from 2019 to 2032 segmented by seven major markets. The report also covers current Multiple Sclerosis (MS) symptoms treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
Geographies Covered
• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan
Study Period: 2019–2032
Multiple Sclerosis (MS) Disease Understanding and Treatment Algorithm
Multiple Sclerosis (MS) Overview
Multiple Sclerosis (MS) is an unpredictable, autoimmune disease that affects the central nervous system. In Multiple Sclerosis, body’s own immune system produces cells and proteins (antibodies) that attack the fatty substance, myelin, which is responsible for protecting the nerve fibers. This is often characterized by relapsing episodes of neurologic impairment followed by remissions.
The damaged myelin forms scar tissue (sclerosis). Often the nerve fiber is also damaged. When any part of the myelin sheath or nerve fiber is damaged or destroyed, nerve impulses traveling to and from the brain and spinal cord are distorted or interrupted.
People with Multiple Sclerosis (MS) generally develop symptoms in their late 20s, experiencing visual and sensory disturbances, limb weakness, gait problems and bladder and bowel syndromes. Initially, they may have partial recovery, but over time they develop progressive disability.
Multiple Sclerosis affected individuals may experience a variety of symptoms, physically, emotionally, mentally and psychologically. The severity and types of symptoms differ among the individuals; thus symptoms differ among different people.
There are four major categories in Multiple Sclerosis. These are: Relapsing-Remitting Multiple Sclerosis, Secondary-Progressive Multiple Sclerosis, Primary-Progressive Multiple Sclerosis, and Progressive-Relapsing Multiple Sclerosis.
There is no single test used to diagnose Multiple Sclerosis. The disease is confirmed when symptoms and signs develop and are related to different parts of the nervous system at more than one interval in time and after other alternative diagnoses have been excluded.
Doctors use different tests to rule out or confirm the diagnosis. In addition to complete medical history, physical examination, and a detailed neurological examination, a doctor may recommend: MRI scans of the brain and spinal cord to look for the characteristic lesions of MS. A special dye or contrast agent may be injected into a vein to enhance brain images of the active MS lesions.
Lumbar puncture (sometimes called a spinal tap) to obtain a sample of cerebrospinal fluid and examine it for proteins and inflammatory cells associated with the disease. Spinal tap analysis also can rule out diseases that may look like MS.
Multiple Sclerosis (MS) Diagnosis and Treatment
It covers the details of conventional and current medical therapies and diagnosis available in the Multiple Sclerosis (MS) market to treat the condition. It also provides country-wise treatment guidelines and algorithms across the United States, Europe, and Japan.
The DelveInsight Multiple Sclerosis (MS) market report gives a thorough understanding of Multiple Sclerosis (MS) symptoms by including disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides Multiple Sclerosis (MS) treatment algorithms and treatment guidelines in the US, Europe, and Japan.
Multiple Sclerosis (MS) Epidemiology
The epidemiology division’s Multiple Sclerosis (MS) symptoms provide insights about the historical and current patient pool and the forecasted trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Key Findings
The disease epidemiology covered in the report provides historical as well as forecasted Multiple Sclerosis (MS) epidemiology segmented as the Total Prevalent Cases of Multiple Sclerosis (MS), Sub-type Specific Prevalent cases of Multiple Sclerosis (MS), Gender Specific Prevalence of Multiple Sclerosis (MS). The report includes the prevalent Multiple Sclerosis (MS) scenario in 7MM, covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2019 to 2032.
Country Wise-Multiple Sclerosis (MS) Epidemiology
The epidemiology segment also provides the Multiple Sclerosis (MS) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
The total 7MM prevalent cases of Multiple Sclerosis (MS) were 1,265000 in 2020.
Multiple Sclerosis (MS) Drug Chapters
The drug chapter segment of the Multiple Sclerosis (MS) report encloses the detailed analysis of Multiple Sclerosis (MS) marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps understand the Multiple Sclerosis (MS) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.
Products detail in the report…
Multiple Sclerosis (MS) Emerging Drugs
NeuroVax: Immune Response BioPharma, Inc.
In March 2020, the company initiated a Phase II, Multi-center, randomized, double-blind, placebo-controlled, two-arm parallel design study of NeuroVax vs. Incomplete Freund’s Adjuvant (IFA) placebo with Secondary Progressive SPMS. The study is estimated to complete on March 2023, with an estimated enrollment of 200 participants.
Products detail in the report…
Multiple Sclerosis (MS) Market Outlook
The Multiple Sclerosis (MS) market outlook of the report helps build a detailed comprehension of the historic, current, and forecasted Multiple Sclerosis (MS) market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers, and demand of better technology.
This segment gives a thorough detail of Multiple Sclerosis (MS) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on an annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, Multiple Sclerosis (MS) market in 7MM is expected to change in the study period 2019–2032.
Key Findings
This section includes a glimpse of the Multiple Sclerosis (MS) market in 7MM. The market size of Multiple Sclerosis (MS) in the seven major markets was found to be USD 22,381 million in 2020.
The United States Market Outlook
This section provides a total of Multiple Sclerosis (MS) market size and market size by therapies in the United States.
The United States accounts for the highest Multiple Sclerosis (MS) market size compared to the EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.
EU-5 Countries: Market Outlook
The total Multiple Sclerosis (MS) market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.
Japan Market Outlook
The total Multiple Sclerosis (MS) market size and market size by therapies in Japan are also mentioned.
Multiple Sclerosis (MS) Drugs Uptake
This section focuses on the rate of uptake of the potential drugs recently launched or expected to get launched in the market during the study period 2019–2032. The analysis covers Multiple Sclerosis (MS) market uptake by drugs, patient uptake by therapies, and drug sales.
This helps understand the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and the comparison of the drugs based on market share and size, which will again be useful in investigating factors important in the market uptake in making financial and regulatory decisions.
Multiple Sclerosis (MS) Pipeline Development Activities
The report provides insights into different therapeutic candidates in Phase II and Phase III stage. It also analyses Multiple Sclerosis (MS) key players involved in developing targeted therapeutics.
Major players NeuroVax (Immune Response BioPharma Inc.), CNM-Au8 (Clene Nanomedicine), Tolebrutinib (SAR442168) (Sanofi), Evobrutinib/M2951 (Merck Healthcare KGaA), Ublituximab (TG Therapeutics, Inc.), ALKS 8700 (Alkermes/Biogen), and Arbaclofen (Arbaclofen ER) (Osmotica Pharmaceutical), and others are being assessed as potential therapies to be available in the market in the coming future.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition, and merger, licensing, and patent details for Multiple Sclerosis (MS) emerging therapies.
KOL Views
To keep up with current market trends, we take KOLs and SME’s opinion working on Multiple Sclerosis (MS) domain through primary research to fill the data gaps and validate our secondary research. Their opinions help understand and validate current and emerging therapy treatment patterns or Multiple Sclerosis (MS) market trends. This will support the clients in potential upcoming novel treatment by identifying the market’s overall scenario and the unmet needs.
Competitive Intelligence Analysis
We perform a Competitive and Market Intelligence analysis of the Multiple Sclerosis (MS) Market by using various Competitive Intelligence tools: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.
Scope of the Report
• The report covers the descriptive overview of Multiple Sclerosis (MS) explaining its causes, signs and symptoms, pathophysiology, and currently available therapies
• Comprehensive insight has been provided into the Multiple Sclerosis (MS) epidemiology and treatment in the 7MM
• Additionally, an all-inclusive account of both the current and emerging therapies for Multiple Sclerosis (MS) provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
• A detailed review of Multiple Sclerosis (MS) market; historical and forecasted is included in the report, covering drug outreach in the 7MM
• The report provides an edge while developing business strategies by understanding trends shaping and driving the global Multiple Sclerosis (MS) market
Report Highlights
• In the coming years, Multiple Sclerosis (MS) market is set to change due to the rising awareness of the disease and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
• The companies and academics are working to assess challenges and seek opportunities that could influence Multiple Sclerosis (MS) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
• Major players are involved in developing therapies for Multiple Sclerosis (MS). The launch of emerging therapies will significantly impact the Multiple Sclerosis (MS) market
• A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Multiple Sclerosis (MS)
• Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities
Multiple Sclerosis (MS) Report Insights
• Patient Population
• Therapeutic Approaches
• Multiple Sclerosis (MS) Pipeline Analysis
• Multiple Sclerosis (MS) Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies
Multiple Sclerosis (MS) Report Key Strengths
• 11 Years Forecast
• 7MM Coverage
• Multiple Sclerosis (MS) Epidemiology Segmentation
• Key Cross Competition
• Highly Analyzed Market
• Drugs Uptake
Multiple Sclerosis (MS) Report Assessment
• Current Treatment Practices
• Unmet Needs
• Pipeline Product Profiles
• Market Attractiveness
• Market Drivers and Barriers
Key Questions
Market Insights:
• What was the Multiple Sclerosis (MS) Market share (%) distribution in 2020, and how would it look in 2032?
• What would be the Multiple Sclerosis (MS) total market Size as well as market Size by therapies across the 7MM during the forecast period (2021–2032)?
• What are the market’s key findings across 7MM, and which country will have the largest Multiple Sclerosis (MS) market Size during the forecast period (2021–2032)?
• At what CAGR, the Multiple Sclerosis (MS) market is expected to grow by 7MM during the forecast period (2021–2032)?
• What would be the Multiple Sclerosis (MS) market outlook across the 7MM during the forecast period (2021–2032)?
• What would be the Multiple Sclerosis (MS) market growth till 2032, and what will be the resultant market Size in the year 2032?
• How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?
Epidemiology Insights:
• What are the disease risk, burden, and unmet needs of Multiple Sclerosis (MS)?
• What is the historical Multiple Sclerosis (MS) patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• What would be the forecasted patient pool of Multiple Sclerosis (MS) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• What will be the growth opportunities in the 7MM concerning the patient population about Multiple Sclerosis (MS)?
• Out of all 7MM countries, which country would have the highest prevalent Multiple Sclerosis (MS) population during the forecast period (2021–2032)?
• At what CAGR is the population expected to grow by 7MM during the forecast period (2021–2032)?
Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:
• What are the current options for the treatment of Multiple Sclerosis (MS)?
• What are the current treatment guidelines for treating Multiple Sclerosis (MS) in the USA, Europe, and Japan?
• What are the Multiple Sclerosis (MS) marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, efficacy, etc.?
• How many companies are developing therapies for the treatment of Multiple Sclerosis (MS)?
• How many therapies are developed by each company for the treatment of Multiple Sclerosis (MS)?
• How many emerging therapies are in the mid-stage and late development stages to treat Multiple Sclerosis (MS)?
• What are the key collaborations (Industry–Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Multiple Sclerosis (MS) therapies?
• What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Multiple Sclerosis (MS) and their status?
• What are the key designations that have been granted for the emerging therapies for Multiple Sclerosis (MS)?
• What are the global historical and forecasted markets of Multiple Sclerosis (MS)?
Reasons to buy
• The report will help in developing business strategies by understanding trends shaping and driving the Multiple Sclerosis (MS) market
• To understand the future market competition in the Multiple Sclerosis (MS) market and Insightful review of the key market drivers and barriers
• Organize sales and marketing efforts by identifying the best opportunities for Multiple Sclerosis (MS) in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
• Organize sales and marketing efforts by identifying the best opportunities for Multiple Sclerosis (MS) market
• To understand the future market competition in the Multiple Sclerosis (MS) market
- 1 Key Insights
- 2 Report Introduction
- 3 Multiple Sclerosis Market Overview at a Glance
- 3.1 Market Share (%) Distribution of Multiple Sclerosis in 2019
- 3.2 Market Share (%) Distribution of Multiple Sclerosis in 2032
- 4 Executive Summary of Multiple Sclerosis
- 5 Disease Background and Overview
- 5.1 Introduction
- 5.2 Signs and Symptoms
- 5.3 Classification Systems
- 5.4 Etiology
- 5.4.1 Genetic Susceptibility
- 5.4.2 Infectious Factors and Viruses
- 5.4.3 Environmental Factors
- 5.5 Risk Factors
- 5.6 Pathogenesis
- 5.7 Pathophysiology
- 5.7.1 Acute Active Plaques
- 5.7.2 Chronic Plaques
- 5.7.3 Remyelinated Plaques
- 5.7.4 Cortical Demyelinated Lesions in Early Multiple Sclerosis
- 5.8 Clinical Manifestations
- 5.9 Diagnosis
- 5.9.1 Diagnostic Criteria
- 6 Treatment of MS
- 7 Management of MS
- 8 Guidelines
- 8.1 ECTRIMS/EAN guidelines on the pharmacological treatment of people with MS
- 8.2 American Academy of Neurology
- 9 Epidemiology and Patient Population
- 9.1 Key Findings
- 9.2 7MM Total Prevalent Patient Population of Multiple Sclerosis
- 9.3 Assumptions and Rationales
- 9.4 The United States
- 9.4.1 Total Prevalent Cases of Multiple Sclerosis in the United States
- 9.4.2 Prevalence of Multiple Sclerosis based on Gender in the United States
- 9.4.3 Phenotype specific prevalent cases of Multiple Sclerosis in the United States
- 9.4.4 Prevalence of Multiple Sclerosis based on Age in the United States
- 9.4.5 EDSS of the United States
- 9.5 EU-5
- 9.5.1 Total Prevalent Cases of Multiple Sclerosis in EU-5
- 9.5.2 Prevalence of Multiple Sclerosis based on Gender in EU-5
- 9.5.3 Phenotype specific prevalent cases of Multiple Sclerosis in EU-5
- 9.5.4 Prevalence of Multiple Sclerosis based on Age in EU-5
- 9.5.5 EDSS of EU-5
- 9.6 Japan
- 9.6.1 Total Prevalent Cases of Multiple Sclerosis in Japan
- 9.6.2 Prevalence of Multiple Sclerosis based on Gender in Japan
- 9.6.3 Phenotype specific prevalent cases of Multiple Sclerosis in Japan
- 9.6.4 Prevalence of Multiple Sclerosis based on Age in Japan
- 9.6.5 EDSS of Japan
- 10 Patient Journey 1
- 11 Patient Journey 2
- 12 Emerging Therapies
- 12.1 NeuroVax: Immune Response BioPharma, Inc.
- 12.1.1 Product Description
- 12.1.2 Other Developmental Activities
- 12.1.3 Clinical Development
- 12.1.4 Clinical Trials Information
- 12.1.5 Product Profile
- 12.2 CNM-Au8: Clene Nanomedicine
- 12.2.1 Product Description
- 12.2.2 Other Developmental Activities
- 12.2.3 Clinical Development
- 12.2.4 Clinical Trials Information
- 12.2.5 Safety and efficacy
- 12.2.6 Product Profile
- 12.3 Tolebrutinib (SAR442168): Sanofi
- 12.3.1 Product Description
- 12.3.2 Other Developmental Activities
- 12.3.3 Clinical Development
- 12.3.4 Clinical Trials Information
- 12.3.5 Safety and efficacy
- 12.3.6 Product Profile
- 12.4 Evobrutinib/M2951: Merck Healthcare KGaA
- 12.4.1 Product Description
- 12.4.2 Clinical Development
- 12.4.3 Clinical Trials Information
- 12.4.4 Safety and efficacy
- 12.4.5 Product Profile
- 12.5 Ublituximab: TG Therapeutics, Inc.
- 12.5.1 Product Description
- 12.5.2 Other Developmental Activities
- 12.5.3 Clinical Development
- 12.5.4 Clinical Trials Information
- 12.5.5 Safety and efficacy
- 12.5.6 Product Profile
- To be continued in the Report…
- 13 Other Emerging Drugs
- 13.1 Apitox: Apimeds Inc.
- 13.2 Nabiximols Oromucosal Spray as Add-on Therapy: GW Pharmaceuticals Ltd.
- 14 Marketed Therapies
- 14.1 Betaseron® (Interferon beta-1b): Bayer HealthCare Pharmaceuticals/Novartis
- 14.1.1 Product Description
- 14.1.2 Mechanism of action
- 14.1.3 Regulatory Milestones
- 14.1.4 Other Developmental Activities
- 14.1.5 Advantages and Disadvantages
- 14.1.6 Safety and Efficacy
- 14.1.7 Product Profile
- 14.2 Avonex (Interferon beta-1a): Biogen
- 14.2.1 Product Description
- 14.2.2 Mechanism of action
- 14.2.3 Regulatory Milestones
- 14.2.4 Other Developmental Activities
- 14.2.5 Advantages and Disadvantages
- 14.2.6 Product Profile
- 14.3 Gilenya (Fingolimod): Novartis
- 14.3.1 Product Description
- 14.3.2 Mechanism of action
- 14.3.3 Regulatory Milestones
- 14.3.4 Other Developmental Activities
- 14.3.5 Advantages and Disadvantages
- 14.3.6 Safety and Efficacy
- 14.3.7 Product Profile
- 14.4 Vumerity (Diroximel fumarate): Alkermes/Biogen
- 14.4.1 Product Description
- 14.4.2 Mechanism of action
- 14.4.3 Regulatory Milestones
- 14.4.4 Other Developmental Activities
- 14.4.5 Advantages and Disadvantages
- 14.4.6 Safety and Efficacy
- 14.4.7 Product Profile
- 14.5 Ocrevus (Ocrelizumab): Biogen/Genentech
- 14.5.1 Product Description
- 14.5.2 Mechanism of action
- 14.5.3 Regulatory Milestones
- 14.5.4 Other Developmental Activities
- 14.5.5 Safety and Efficacy
- 14.5.6 Product Profile
- 15 Multiple Sclerosis: 7 Major Market Analysis
- 15.1 Key Findings
- 15.2 Market Size of Multiple Sclerosis in 7MM
- 15.3 Market Size of Multiple Sclerosis by Therapies
- 16 Market Outlook
- 16.1 United States Market Size
- 16.1.1 Total Market Size of Multiple Sclerosis in the United States
- 16.1.2 Market Size of Multiple Sclerosis by Therapies in United States
- 16.2 EU-5 Market Size
- 16.2.1 Total Market size of Multiple Sclerosis in EU-5
- 16.2.2 Market Size of Multiple Sclerosis Therapies in EU-5
- 16.3 Japan
- 16.3.1 Total Market size of Multiple Sclerosis in Japan
- 16.3.2 Market Size of Multiple Sclerosis by Therapies in Japan
- 17 Expenditure, Utilization, and Cost of Specialty Drugs for Multiple Sclerosis in the US
- 17.1 Total Annual Utilization and Reimbursement of All Study Drugs
- 17.2 Total Annual Reimbursement of All Study Drugs
- 17.3 Annual Cost per Prescription of Each Study Drug
- 17.4 Market Share
- 18 KOL Views
- 19 Unmet Needs
- 20 Market Drivers
- 21 Market Barriers
- 22 SWOT Analysis
- 23 Appendix
- 23.1 Bibliography
- 23.2 Report Methodology
- 24 DelveInsight Capabilities
- 25 Disclaimer
- 26 About DelveInsight
- Table 1: Summary of Multiple Sclerosis, Market, Epidemiology, and Key Events (2019–2032)
- Table 2: Differential Diagnosis of Multiple Sclerosis
- Table 3: Symptomatic treatment of Multiple Sclerosis
- Table 4: Total Prevalent Patient Population of Multiple Sclerosis in 7MM in 000’s (2019–2032)
- Table 5: Total Prevalent Cases of Multiple Sclerosis in the United States in 000's (2019–2032)
- Table 6: Prevalence of Multiple Sclerosis based on Gender in the United States in 000's (2019–2032)
- Table 7: Phenotype specific Prevalent cases of Multiple Sclerosis in the United States in 000's (2019–2032)
- Table 8: Prevalence of Multiple Sclerosis based on Age in the United States in 000's (2019–2032)
- Table 9: EDSS of the United States in 000’s (2019–2032)
- Table 10: Total Prevalent Cases of Multiple Sclerosis in EU-5 in 000's (2019–2032)
- Table 11: Prevalence of Multiple Sclerosis based on Gender in EU-5 in 000's (2019–2032)
- Table 12: Phenotype specific Prevalent cases of Multiple Sclerosis in EU-5 in 000's (2019–2032)
- Table 13: Prevalence of Multiple Sclerosis based on Age in EU-5 in 000's (2019–2032)
- Table 14: EDSS of EU-5 in 000's (2019–2032)
- Table 15: Total Prevalent Cases of Multiple Sclerosis in Japan in 000's (2019–2032)
- Table 16: Prevalence of Multiple Sclerosis based on Gender in Japan in 000's (2019–2032)
- Table 17: Phenotype specific Prevalent cases of Multiple Sclerosis in Japan in 000's (2019–2032)
- Table 18: Prevalence of Multiple Sclerosis based on Age in Japan in 000’s (2019–2032)
- Table 19: EDSS of Japan in 000’s (2019–2032)
- Table 20: NeuroVax, Clinical Trial Description, 2021
- Table 21: CNM-Au8, Clinical Trial Description, 2021
- Table 22: Tolebrutinib , Clinical Trial Description, 2021
- Table 23: Evobrutinib, Clinical Trial Description, 2021
- Table 24: Ublituximab, Clinical Trial Description, 2021
- Table 25: ALKS 8700, Clinical Trial Description, 2021
- Table 26: Arbaclofen, Clinical Trial Description, 2021
- Table 27: Masitinib, Clinical Trial Description, 2021
- Table 28: Fenebrutinib, Clinical Trial Description, 2021
- Table 29: 7 Major Market Size of Multiple Sclerosis in USD Million (2019–2032)
- Table 30: 7 Major Market Size of Multiple Sclerosis by Therapies in USD Million (2019–2032)
- Table 31: United States Market Size of Multiple Sclerosis in USD Million (2019–2032)
- Table 32: United States Market Size of Multiple Sclerosis by Therapies in USD Million (2019–2032)
- Table 33: EU-5 Market Size of Multiple Sclerosis in USD Million (2019–2032)
- Table 34: EU-5 Market Size of Multiple Sclerosis by Therapies in USD Million (2019–2032)
- Table 35: Japan Market Size of Multiple Sclerosis in USD Million (2019–2032)
- Table 36: Japan Market Size of Multiple Sclerosis by Therapies in USD Million (2019–2032)Figure 1: Types of Multiple Sclerosis
- Figure 2: The Most Common Risk Factors for Multiple Sclerosis (MS)
- Figure 3: Mechanisms of action for IFNβ in multiple sclerosis. Interferon beta exerts its biological effects by binding to specific receptors on the surface of human cells. This binding initiates a complex cascade of intracellular events that leads to the expression of numerous interferon‐induced gene products and markers
- Figure 4: Total Prevalent Population of Multiple Sclerosis in 7MM in 000’s (2019–2032)
- Figure 5: Total Prevalent Cases of Multiple Sclerosis in the United States in 000's (2019–2032)
- Figure 6: Prevalence of Multiple Sclerosis based on Gender in the United States in 000's (2019–2032)
- Figure 7: Phenotype specific Prevalent cases of Multiple Sclerosis in the United States in 000's (2019–2032)
- Figure 8: Prevalence of Multiple Sclerosis based on Age in the United States in 000's (2019–2032)
- Figure 9: EDSS of the United States in 000’s (2019–2032)
- Figure 10: Total Prevalent Cases of Multiple Sclerosis in EU-5 in 000’s (2019–2032)
- Figure 11: Prevalence of Multiple Sclerosis based on Gender in EU-5 in 000’s (2019–2032)
- Figure 12: Phenotype specific Prevalent cases of Multiple Sclerosis in EU-5 in 000’s (2019–2032)
- Figure 13: Prevalence of Multiple Sclerosis based on Age in EU-5 in 000's (2019–2032)
- Figure 14: EDSS of EU-5 in 000’s (2019–2032)
- Figure 15: Total Prevalent Cases of Multiple Sclerosis in Japan in 000's (2019–2032)
- Figure 16: Prevalence of Multiple Sclerosis based on Gender in Japan in 000's (2019–2032)
- Figure 17: Phenotype specific Prevalent cases of Multiple Sclerosis in Japan in 000's (2019–2032)
- Figure 18: Prevalence of Multiple Sclerosis based on Age in Japan in 000's (2019–2032)
- Figure 19: EDSS of Japan in 000’s (2019–2032)
- Figure 20: 7 Major Market Size of Multiple Sclerosis in USD Million (2019–2032)
- Figure 21: 7 Major Market Size of Multiple Sclerosis by Therapies in USD Million (2019–2032)
- Figure 22: Total Market Size of Multiple Sclerosis in the United States, USD Million (2019–2032)
- Figure 23: The United States Market Size of Multiple Sclerosis by Therapies in USD Million (2019–2032)
- Figure 24: Total Market Size of Multiple Sclerosis in EU-5, USD Million (2019–2032)
- Figure 25: EU-5 Market Size of Multiple Sclerosis by Therapies in USD Million (2019–2032)
- Figure 26: Market Size of Multiple Sclerosis in Japan, USD Million (2019–2032)
- Figure 27: The Japan Market Size of Multiple Sclerosis by Therapies in USD Million (2019–2032)
- Figure 28a: Annual Reimbursement and Spending Trends of Multiple Sclerosis Drugs, 2008–2019, by Route of Administration
- Figure 29b: Annual Reimbursement and Spending Trends of Multiple Sclerosis Drugs, 2008–2019, by Route of Administration
- Figure 30c: Annual Reimbursement and Spending Trends of Multiple Sclerosis Drugs, 2008–2019, by Route of Administration
- Figure 31a: Annual Cost per Prescription of Multiple Sclerosis Drugs, 2008–2019, by Route of Administration
- Figure 32b: Annual Cost per Prescription of Multiple Sclerosis Drugs, 2008–2019, by Route of Administration
- Figure 33c: Annual Cost per Prescription of Multiple Sclerosis Drugs, 2008–2019, by Route of Administration
- Figure 34a: Annual Market Share of Each Drug Category, Represented as Percentage, 2008–2019
- Figure 35b: Annual Market Share of Each Drug Category, Represented as Percentage, 2008–2019
Research Assistance
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook